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The ability to make specific perturbations to biolog-
ical molecules in a cell or organism is a central
experimental strategy in modern research biology.
We have developed a general technique in which
the stability of a specific protein is regulated by
a cell-permeable small molecule. Mutants of the
Escherichia coli dihydrofolate reductase (ecDHFR)
were engineered to be degraded, and, when this
destabilizing domain is fused to a protein of interest,
its instability is conferred to the fused protein result-
ing in rapid degradation of the entire fusion protein.
A small-molecule ligand trimethoprim (TMP) stabi-
lizes the destabilizing domain in a rapid, reversible,
and dose-dependent manner, and protein levels in
the absence of TMP are barely detectable. The ability
of TMP to cross the blood-brain barrier enables the
tunable regulation of proteins expressed in the
mammalian central nervous system.
INTRODUCTION
Numerous perturbation techniques have been developed to
study gene function in biological systems. The Cre-Lox tech-
nology is a useful approach to inactivate genes in mice. Tissue-
or cell-specific promoters can be used to drive Cre expression
thus providing a degree of temporal and spatial control to the
disruption of targeted genes (Gaveriaux-Ruff and Kieffer,
2007). However, this approach is not reversible, and identifying
a suitable promoter can be difficult. Strategies to conditionally
regulate the transcription of genes (e.g., the tetracycline-
regulated transactivator) are widely used to control gene
expression (Furth et al., 1994). Protein levels can also be regu-
lated by targeting the mRNA transcripts using RNA interference
(Xia et al., 2002). All of the techniques that target the precursor
DNA or mRNA molecules encoding a protein of interest suffer
from inevitable delays following the perturbation. Existing protein
molecules must be degraded, so the experimental delay is
dictated by the biological half-life of the protein under study.
Targeting proteins directly, rather than the DNA or mRNA
molecules that encode them, is a more direct and rapid experi-
mental strategy. In the past decade, a number of conditionalChemistry & Biology 17, 981–9protein regulation systems have been developed that utilize the
cellular degradation machinery. In Varshavsky’s early system
a temperature-sensitive mutant of mammalian DHFR (DHFRts)
bearing N-terminal arginine residue, a destabilizing residue by
the N-end rule, was found to be stable at a permissive tempera-
ture of 23C but unstable at 37C (Dohmen et al., 1994; Le´vy
et al., 1999). Addition of methotrexate, a high-affinity ligand for
mammalian DHFR, to cells expressing Arg-DHFRts partially in-
hibited degradation of the protein (Le´vy et al., 1999). This was
an important demonstration that a small-molecule ligand can
stabilize a protein otherwise targeted for degradation in cells.
In 2003, Crabtree and coworkers demonstrated the rapid and
reversible regulation of the GSK-3b kinase fused to an unstable
triple mutant of the FRB domain (FRB*) using the rapamycin-
derivative C20-MaRap (Stankunas et al., 2003). MaRap induces
a heterodimerization event between the FRB*-GSK3b fusion and
ubiquitously expressed FKBP12 to stabilize the FRB* fusion and
restore the function of the fused kinase. The FRB*-GSK3b was
inducibly stabilized in cells as well as in embryos in vivo (Liu
et al., 2007). This system demonstrated that ligand-dependent
stability represented an attractive strategy to regulate the func-
tion of a specific protein in a complex biological environment.
We previously developed a strategy in which a cell-permeable
ligand is used in conjugation with a single genetically encoded
domain to regulate any protein of interest. A small domain can
be fused to any gene, and a fusion protein is produced as a result
of this specific genetic perturbation. Mutants of the human
FKBP12 protein were engineered to be metabolically unstable
in the absence of its high-affinity ligand, Shield-1 (Banaszynski
et al., 2006). We call these mutants destabilizing domains
(DDs) and observe that the instability of a DD conferred to any
fused partner protein results in degradation of the entire fusion
protein by the proteasome. Shield-1 binds to and stabilizes the
DD in a dose-dependent manner. The genetic fusion of the DD
to the gene of interest ensures specificity, and small-molecule
control confers reversibility and dose dependence to protein
stability and function.
Building on our experiences with the FKBP-derived DDs, we
chose E. coli dihydrofolate reductase (ecDHFR) as a candidate
protein to engineer a second destabilizing domain with improved
properties. The 159-residue enzyme catalyzes the reduction of
dihydrofolate to tetrahydrofolate, a cofactor that is essential for
several steps in prokaryotic primary metabolism (Schnell et al.,
2004). Numerous inhibitors of DHFR have been developed as
drugs (Schweitzer et al., 1990), and one such inhibitor,88, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 981
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mammalian DHFR (Matthews et al., 1985). This large therapeutic
window renders TMP ‘‘biologically silent’’ in mammalian cells.
The specificity of the ecDHFR-TMP interaction, coupled with
the commercial availability and attractive pharmacological
properties of TMP, makes this protein-ligand pair ideal for
development as a DD system as presaged in another context
by Varshavsky (Dohmen et al., 1994; Johnston et al., 1995;
Le´vy et al., 1999).
RESULTS
Screening Strategies to Engineer DDs
To engineer mutants that display ligand-dependent stability, we
designed a cell-based screen using yellow fluorescent protein
(YFP) as a reporter for ecDHFR stability. The strategy was de-
signed to identify mutants possessing the desired characteris-
tics of a destabilizing domain: low protein levels in the absence
of TMP (i.e., low basal stability), large dynamic range, robust
and predictable dose-response behavior, and rapid kinetics of
degradation. We used error-prone PCR (Atwood-Moore et al.,
2005; Zaccolo et al., 1996) to generate libraries of ecDHFR
mutants based on the parental sequence (see Figures S1A–
S1D available online), as well as two-point mutants (Y100I and
G121V) that are known to compromise enzymatic activity
(Figures S1E and S1F) (Adams et al., 1991; Cameron and Ben-
kovic, 1997). Two libraries were prepared with the ecDHFR
mutants cloned in-frame at either the 50- or 30-ends of the YFP
gene, and a retroviral expression system was used to stably
transduce the libraries into NIH 3T3 fibroblasts. Fluorescence-
activated cell sorting (FACS) was used to screen the libraries
of candidate DDs. Cells were first sorted in the absence of
TMP, where we selected cells that exhibited low levels of YFP
expression. This population was then treated with 10 mM TMP
for 24 hr, at which point YFP-expressing cells were isolated by
FACS. Cells were evenly split into two populations and dosed
with either 1 or 0.1 mM TMP, at which point a third sort was per-
formed. This step allowed us to isolate cells expressing mutants
that were responsive to lower concentrations of TMP. The fourth
and final stepwas designed to enrich for ecDHFRmutants exhib-
iting fast kinetics of degradation, as cells exhibiting low fluores-
cence levels were collected 4 hr following removal of TMP from
the media. After four rounds of sorting the cells were allowed to
recover, their genomic DNA was extracted, and candidate DDs
were amplified by PCR and isolated.
Characterization of ecDHFR Mutants that Display
TMP-Dependent Stability
Genes encoding individual ecDHFR-YFP fusions were trans-
duced into NIH 3T3 cells, and YFP fluorescence levels were
measured in the absence and presence of 10 mM TMP. Mutants
displaying low basal fluorescence levels and also high dynamic
range were then sequenced (Tables S1A and S1B). From the
screen using ecDHFR fused to the N terminus of YFP, we chose
three mutants (R12Y/Y100I, R12L/Y100I, and R98H/F103S) for
further analysis, and two mutants (F103L and N18T/A19V) were
chosen from the C-terminal DD screen. Treating cells with
various concentrations of TMP caused YFP levels to increase
in a dose-dependent manner as measured by analytical flow982 Chemistry & Biology 17, 981–988, September 24, 2010 ª2010 Elcytometry (Figures 1A and 1B). DDs fused to the N terminus of
YFP are fully stabilized by 1 mM TMP and display improved
dynamic range. The R98H/F103S mutant is stabilized 100-fold
upon treatment with TMP compared to a 31-fold increase in
YFP levels for the Y100I mutant (Figure 1A). The enhanced
dynamic range is largely the result of more effective destabiliza-
tion under nonpermissive conditions. The C-terminal DD
screen produced mutants with wide dynamic ranges of YFP
expression (between 63- and 93-fold) that are stabilized by lower
concentrations of TMP (Figure 1B). All of the DDs caused drastic
destabilization of the YFP protein in the absence of TMP. YFP
fluorescence, measured by analytical flow cytometry, was barely
above the autofluorescence of untransduced NIH 3T3 cells
(Figure S1G).
We next investigated the kinetics of destabilized domain
rescue and degradation. YFP fluorescence levels of each of
the DDs increased at a similar rate upon treatment with TMP
(Figures S1H and S1I). To measure the rates of protein degrada-
tion upon switching to nonpermissive conditions, mutants were
stabilized with TMP for 24 hr at which time TMP was removed
from the culture media and cells were assayed for YFP fluores-
cence. The majority of mutants reach basal fluorescence levels
within 4 hr, as anticipated from the final step of the screening
strategy (Figures S1J and S1K). To investigate the source of
proteolytic activity, cells stably transduced with either the
R12Y/Y100I-YFP or YFP-N18T/A19V fusion proteins were
cultured in the presence or absence of 10 mM TMP. Cells were
also treated with inhibitors of either proteasome- or lysosome-
mediated degradation (Reusch et al., 1999). Only cells treated
with the proteasome inhibitor MG132 exhibited reduced
degradation of DD-YFP fusion protein upon switching to nonper-
missive conditions, suggesting that degradation is mediated by
proteasome (Figure S1L).
We have thus far demonstrated that ecDHFR-derived DDs
destabilize YFP when fused to the terminus for which they
were screened and identified. In situations where proteins may
not functionally tolerate N- or C-terminal fusions, it would be
preferable to have destabilizing domains that can regulate
protein levels when spliced into a tolerant domain within the
protein of interest. To investigate whether the ecDHFR-derived
DDs could confer instability in this context, we spliced the
sequences for either the R12Y/Y100I or the N18T/A19V DD
between the codons encoding residues 157 and 158 of the
YFP gene, which is a site within YFP known to tolerate insertions
(Magliery et al., 2005). To accommodate the folding require-
ments of these globular proteins we tethered the N and C termini
of the ecDHFRdomain to the YFP splice site using linkers varying
from 2 to 19 residues on either side of the ecDHFR domain. The
internal R12Y/Y100I domain dramatically decreased YFP fluo-
rescence levels in the absence of TMP, and YFP levels were
stabilized upon addition of TMP (Figure 1C). Although the
N18T/A19V DD is strongly destabilizing when fused to the C
terminus of YFP, this mutant was not as effective as the R12Y/
Y100I mutant when spliced internally (Figure S1M).
FKBP- and ecDHFR-Derived DDs Are Tunably
and Predictably Regulated by Their Respective Ligands
One of the goals of this study was to develop a DD system that,
when used in combination with the FKBP-derived DD systemsevier Ltd All rights reserved
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Figure 1. Characterization of ecDHFR Mutants that Display TMP-
Dependent Stability
(A) NIH 3T3 cells stably transduced with the indicated ecDHFR-YFP fusions
were treated with 3-fold dilutions of TMP (30 mM to 1 nM) or mock-treated
with DMSO and monitored by analytical flow cytometry. Data are represented
as the average median fluorescence intensity (±SD) and normalized against
the average MFI of untransduced cells.
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Chemistry & Biology 17, 981–9(Banaszynski et al., 2006), would allow simultaneous regulation
of two proteins or groups of proteins. To demonstrate the
orthogonality of the FKBP-derived and ecDHFR-derived DD
systems, we stably transduced both the FKBP-derived L106P
DD fused to mCherry and the ecDHFR-derived R12Y/Y100I DD
fused to YFP into NIH 3T3 cells. Doubly transduced cells were
treated with various concentrations of Shield-1 and TMP and
analyzed over the course of one week (Figure 2A). Epifluores-
cence microscopy images of the doubly transduced cells dosed
with indicated combinations of TMP and Shield-1 are also shown
(Figure 2B). The close correspondence of the observed fluores-
cence levels to those predicted from dose-response experi-
ments highlights the ability of this system to regulate two
proteins of interest independently of one another. As expected,
Shield-1 and TMP do not have any effects on their orthogonal
DDs (Figures S2A and S2B).
Regulation of Transmembrane Proteins
A previous attempt to regulate CD8a, a transmembrane glyco-
protein found on the surface of T cells, resulted in modest levels
of regulation at the cell surface (Banaszynski et al., 2006).
Because N18T/A19V and R12Y/Y100I ecDHFR are both more
potent DDs when fused to the C terminus of YFP, we suspected
that the ecDHFR-derived DDsmight offer improved regulation of
CD8a expression. To test this theory, we fused either the N18T/
A19V or R12Y/Y100I DD to the C terminus of CD8a and trans-
duced these fusions into NIH 3T3 cells. Flow cytometry was
used to quantitate levels of CD8a at the cell surface, where we
observed a significant decrease in CD8a expression in the
absence of TMP. Upon treatment of cells with 10 mM TMP for
24 hr, the N18T/A19V fusion showed higher expression of
CD8a, and therefore greater dynamic range, than the R12Y/
Y100I fusion (Figure 3A). TMP-mediated stabilization for 24 hr
followed by withdrawal of the ligand for 24 hr (+/; in Figure 3A)
produced protein levels nearly as low as cells maintained under
nonpermissive conditions. Encouraged by these results, we
tested the ability of these DDs to destabilize a more structurally
complex transmembrane protein, the b2-adrenergic receptor
(b2AR) (Cherezov et al., 2007), which is a member of the GPCR
family of integral membrane proteins. Cells were stably trans-
duced with either the N18T/A19V or R12Y/Y100I DDs fused to
the 30-end of the b2AR gene, and we observed low levels of
b2AR expression in the absence of TMP. Addition of TMP caused
protein levels to increase, and TMP-mediated stabilization for
24 hr followed by 24 hr under TMP-free nonpermissive conditions
returned b2AR levels to the low background level (Figure 3B).
Regulating DDs in Rat Brain
The commercial availability, oral bioavailability, and low cost of
TMP make this ecDHFR-derived DD system particularly(B) NIH 3T3 cells stably transduced with the indicated YFP-ecDHFR fusions
were treated as in (A).
(C) The R12Y/Y100I destabilizing domain was spliced into the YFP gene
between the codons encoding residues 157 and 158. Linkers of varying length
were used to flank the ecDHFR gene. These constructs were stably expressed
in NIH 3T3 cells, and cells were either mock-treated or dosed with 10 mM TMP
for 24 hr prior to analysis by flow cytometry.
See also Figure S1 and Table S1.
88, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 983
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Figure 2. FKBP- and ecDHFR-Derived DDs
Are Tunably and Predictably Regulated
Using Their Respective Ligands
(A) NIH 3T3 cells doubly transduced with ecDHFR-
derived R12Y/Y100I-YFP and the FKBP-derived
L106P-mCherry were dosed with varying concen-
trations of TMP (black) and Shield-1 (red), and
fluorescence was monitored by flow cytometry at
the time points indicated. Predicted MFI values
(thick lines) were generated using a previous
dose-response study of the same cell line. Data
are presented as the average MFI ±SD and
normalized against the average MFI of cells dosed
with 10 mMTMPand 3 mMShield-1, whichwere set
at 100%.
(B) NIH 3T3 cells described in (A) were plated onto
two well chamber slides and treated for 24 hr with
concentrations of TMP and Shield-1 correspond-
ing to the conditions used in (B). Live cells were
visualized by epifluorescence microscopy.
See also Figure S2.
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(Banaszynski et al., 2008). To test the suitability of this new DD
system for use within the central nervous system of living rats,
we injected recombinant lentivirus encoding either R12Y/
Y100I-YFP or YFP-N18T/A19V into the striatum of adult rats
(n = 6). Half of the animals received TMP in their drinking water
(0.2 mg/ml final concentration), and the water was exchanged
daily over 3 weeks. The animals were sacrificed 3 weeks after
injection of the lentivirus, and the brain tissue was fixed and
stained for YFP expression. Immunohistochemical analysis of
samples from animals that received TMP showed strong
induction of YFP expression (Figures 4B and 4D), whereas YFP
was barely detectable in animals that received no TMP (Figures
4A and 4C). This experiment demonstrates the first use to our
knowledge of the destabilizing domain technology to condition-
ally regulate the stability of transgenes expressed in the
mammalian central nervous system.
DISCUSSION
The first DD technology was developed based on the human
FKBP12 protein bearing a cavity-forming F36V mutation, as
a family of FKBP ligands containing corresponding synthetic
‘‘bumps’’ has already been developed and found to be nontoxic
in cultured cells and animals (Iuliucci et al., 2001). These high-
affinity ligands bind to FKBP(F36V) more tightly than wild-type
FKBP12 by three orders of magnitude (Clackson et al., 1998).
Based on this protein-ligand pair, we used error-prone PCR
and FACS-based screening to identify dozens of FKBP(F36V)
mutants whose stability can be modulated by a small-molecule
ligand Shield-1. The resulting FKBP-derived DD system confers
instability to a wide range of proteins and has been shown to
confer ligand-dependent stability to kinases, cell cycle regula-
tory proteins and small GTPases expressed in cultured cells
(Banaszynski et al., 2006). The FKBP-derived DD was further
demonstrated to work well in vivo, regulating the stability of984 Chemistry & Biology 17, 981–988, September 24, 2010 ª2010 Elsecreted proteins in a dose-dependent manner in mice (Banas-
zynski et al., 2008). The FKBP system has also been used with
success in other organisms, such as Toxoplasma (Herm-Go¨tz
et al., 2007) and Plasmodium (Russo et al., 2009; Dvorin et al.,
2010).
Like the FKBP-derived DDs, the ecDHFR-derived DDs
reported in this manuscript confer instability to a fused protein,
resulting in rapid degradation of the protein upon withdrawal of
the ligand TMP. Characterization of the ecDHFR-derived DDs
revealed that the DDs behave very similarly to the FKBP-derived
DDs, and the two DD systems work orthogonally as demon-
strated in mammalian cells. However, there are notable
differences between the two systems. The C-terminal
ecDHFR-derived DDs are much more effective at destabilizing
the fusion protein than the FKBP-derived L106P DD. Whereas
the destabilizing effects of the L106P domain are reduced
when fused at the C terminus of YFP, the ecDHFR-derived
DDs F103L and N18T/A19V are very successful at reducing the
protein levels when fused to the C terminus of YFP, with
negligible protein levels observed in the absence of TMP.
Fusion of the FKBP-derived L106P DD to the C terminus of
a single-transmembrane protein CD8a is only modestly destabi-
lizing, as a significant amount of protein is trafficked to the
membrane in the absence of Shield-1 (Banaszynski et al.,
2006). When we fuse DHFR N18T/A19V domain to CD8a, we
observe far greater destabilization of CD8a relative to the
L106P fusion. Encouraged by this result, we applied the DD
technology to the more structurally complex and therapeutically
relevant integral transmembrane protein, human b2AR, a G
protein-coupled receptor (GPCR). TMP-dependent stability of
b2AR was achieved with 10-fold increase in b2AR-DD expres-
sion upon addition of the ligand. GPCRs represent an important
class of drug targets for the pharmaceutical industry and
currently 30% of marketed drugs act on this family of pro-
teins (Hopkins and Groom, 2002). GPCRs play key roles in
biological processes such as cellular metabolism, cell growth,sevier Ltd All rights reserved
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Figure 3. Regulation of Transmembrane Proteins
(A) The ecDHFRmutants N18T/A19V and R12Y/ Y100I were fused to the 30 end
of the CD8a gene and were stably transduced into NIH 3T3 cells. Cells were
divided into three pools, and the first population () was mock-treated, and
the second population (+) was treated with 10 mM TMP for 24 hr. The third
population (+/) was treated with 10 mM TMP for 24 hr and then washed
with media and cultured for 24 hr in the absence of TMP. Live cells were
probed with a FITC-conjugated anti-CD8a antibody and assayed by flow
cytometry. Data are presented as the average MFI ±SD and normalized
against the average MFI of untransduced NIH 3T3 cells that were also stained
with antibody.
(B) The N18T/A19V and R12Y/Y100I DDs were fused to the 30 end of the b2AR
gene and these fusions were stably expressed in NIH 3T3 cells. As a positive
control, unfused b2AR was stably expressed and analyzed alongside both
fusions. The cells were divided into three pools as described in (A) and
analyzed by flow cytometry. All b2AR genes encoded an N-terminal FLAG
epitope. Live cells were probed with Alexa Fluor 488-labeled M1 anti-FLAG
antibody, which only recognizes the epitope expressed at the cell surface.
A B
DC
Figure 4. Regulating DD-YFP and YFP-DD in Rat Brain
Adult rats received an injection of recombinant lentivirus (rLV) encoding R12Y/
Y100I-YFP in the left striatum and YFP-N18T/A19V in the right striatum. Immu-
nohistochemistry of rat brain tissue 3 weeks post rLV injection in animals that
received (A) no TMP and (B) 0.2 mg/ml TMP in drinking water. rLV-ecDHFR
R12Y/Y100I-YFPwith (C) no TMP (D) 0.2 mg/ml TMP. The 40 mmcoronal slices
were probed with GFP antibody, followed by incubation in biotinylated
secondary antibody. The tissues were visualized with avidin-biotin-peroxidase
complex using 3,3-diaminobenzidine as chromogen. Scale bar in (A)
represents 100 mm, and insets represent 20 mm.
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taken place in the past decades to understand the function
and pathways involved with these membrane proteins. These
new ecDHFR-derived DDs may prove to be important tools for
probing the functional roles of this large and therapeutically
important family of cell surface receptors.Chemistry & Biology 17, 981–9Another important advantage of using the ecDHFR-derived
DD system is that the ligand is commercially available, inexpen-
sive, and possesses good pharmacological characteristics. The
drug can be administered orally, a less invasive and more
convenient method of drug administration than IP injection or
IV administration. TMP-dosed rats presented no adverse effects
such as loss of body weight or diarrhea during this study, even
when dosed at 0.4 mg/ml (twice the dose used to regulate
transgenes) for 6 weeks (data not shown). TMP crosses the
blood-brain barrier (Barling and Selkon, 1978), allowing the
conditional regulation of specific proteins within the central
nervous system of living rodents. TMP also passes the placental
barrier (Schulz, 1972), with teratogenicity observed only when
rats are given very high concentrations of TMP. Many genes
misregulated in diseases such as cancer exhibit embryonic lethal
phenotypes in knockout mouse models. For example, the
disruption of genes involved in angiogenesis such as vascular
endothelial growth factor or vascular endothelial receptor
tyrosine phosphatase results in vascular defects, leading to
embryonic lethality (Carmeliet et al., 1996; Dominguez et al.,
2007) and precluding study of the roles of these proteins in tumor
angiogenesis. The DHFR-derived DD system may be a suitable
alternative for in vivo regulation of proteins that are required
during embryonic development. Pregnant mice carrying fetuses
encoding genes targeted with the ecDHFR-derived DD can be
administered TMP during gestation to maintain protein levels
necessary for proper development of the embryos.88, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 985
Chemistry & Biology
A Novel DHFR-Derived Destabilizing DomainThe rapid switch-like behavior of the DD system makes it
a powerful conditional perturbation method, and the ability to
tunably regulate protein levels with a high degree of predictability
makes the destabilizing domains valuable in broader contexts.
For instance, a knowledge of the proteins comprising a signaling
network is necessary but not sufficient for a full understanding of
the behavior of the system. Researchers can utilize the DD
systems to study howmolecules comprising a signaling network
are ‘‘wired’’ together through intermolecular interactions or
diffusible second messengers by perturbing one member of
a circuit and observing the effects of this perturbation on the
other members of the circuit. This form of sensitivity analysis,
performed on the proteins of an intact signaling circuit in a living
cell, will enable researchers to deconvolute the interactions
between signaling proteins andwill ultimately lead to quantitative
models of the signaling circuit that can both explain as well as
predict the consequences of perturbations.
Thus far, all of the systems described above operate in a way
where the protein level is maintained in the presence of ligand.
Recently a conditional protein stability technology was devel-
oped by which proteins are rapidly depleted in the presence of
the plant hormone, auxin (Nishimura et al., 2009). In this system,
the targeted protein is fused to the AUX/IAA transcriptional
repressor (Aid). Degradation of Aid is mediated by the F-box
transport inhibitor response 1 protein (TIR1), a plant F-box
protein that is part of SCF E3 ubiquitin ligase complex. Addition
of auxin promotes the interaction between SCF-TIR1 E3 ubiqui-
tin ligase complex and Aid, resulting in degradation of Aid and
any fused partner protein. This system represents a promising
approach for using a ligand to destabilize (rather than stabilize)
targeted proteins, and obviates the need to continuously
administer the ligand until the desired experimental window.
Depending on the system used the cost of maintenance dosing
could be prohibitive, not to mention the effect of long-term
administration of ligand to the animals. While the auxin-based
system has the advantage of lacking off-target effects in
mammalian cells, this system requires two genetic elements
rather than one: researchers must introduce a transgene encod-
ing the F-box protein, TIR1, as well as a second gene encoding
the Aid-tagged gene of interest. A system requiring only a single
genetic manipulation would be more desirable. Ideally, fusion of
a single DD to a targeted protein would confer ligand-dependent
stability, but in the opposite sense of the current DDs.
SIGNIFICANCE
We have developed a general method to regulate stability of
a specific protein in a rapid, reversible, and tunable manner
using a commercially available small molecule. Mutants of
E. coli dihydrofolate reductase (ecDHFR) protein were
engineered to be degraded when expressed in mammalian
cells. When this destabilizing domain (DD) is fused to
a protein of interest, its instability is conferred to the fused
protein, resulting in rapid degradation of the entire fusion
protein by the proteasome. Trimethoprim (TMP) is a high-
affinity ligand for ecDHFR that stabilizes fusion proteins in
a dose-dependent manner, and protein levels in the absence
of TMP are negligible. This ecDHFR-TMP DD system works
orthogonally to the existing FKBP/Shld1-based DD system,986 Chemistry & Biology 17, 981–988, September 24, 2010 ª2010 Elallowing simultaneous regulation of two proteins indepen-
dently. The ecDHFR-DD system successfully regulates
transmembrane proteins that were difficult to target with
the FKBP-DD, such as a GPCR protein, beta2-adrenergic
receptor. We have shown a successful regulation of
transgenes expressed in rat brain by oral administration of
TMP. The ability of TMP to cross the blood-brain barrier
(BBB) enables the tunable regulation of proteins expressed
in cells foundwithin themammalian central nervous system.
Finally, TMP passes the placental barrier, possibly allowing
tunable regulation of genes essential in embryonic develop-
ment. The DHFR-derived DD system may prove useful in
dissecting the role of genes involved in cancer and other
diseases in vivo that previously were considered difficult
due to essentiality of the genes in embryonic development.
Controlling protein function directly using a small-molecule
ligand is a more attractive approach than targeting pre-
cursor DNA or mRNA, as direct targeting of protein is rapid
and is not limited by the intrinsic half-life of the targeted
proteins.
EXPERIMENTAL PROCEDURES
ecDHFR Library Generation
Diversity in the ecDHFR sequence was generated using a combination of
error-prone PCR (Atwood-Moore et al., 2005) and nucleotide analog mutagen-
esis (Zaccolo et al., 1996). Three ecDHFR genes were used as templates:
parental, Y100I, and G121V (see Figure S1 for a description of the parental
sequence). For each of these templates, three mutagenesis conditions were
used to generate diversity. Condition set A utilized the nonnatural nucleotides
8-oxo-dGTP and dPTP to encourage nucleotide misincorporation. Condition
set B utilized 4 ng template, 0.5 mM of each oligonucleotide primer, 3.75 units
of Taq polymerase, 5 mM MgCl2, 0.2 mM MnCl2, 0.4 mM dNTPs, and an
excess 0.2 mM of dATP and dCTP. Condition set C was identical to B, but
dGTP and dTTP were used in excess instead of dATP and dCTP.
Library Screening and Validation
Calculated library diversity was 3 3 104 members for the ecDHFR-YFP library
and 1.53 105members for the YFP-ecDHFR library. Screeningwas performed
as described in the text. Upon completion of the fourth sort the cells were
allowed to recover in media, and genomic DNA was obtained using QIAGEN
DNeasy kit. To isolate individual ecDHFR mutants from the pool of genomic
DNA, the ecDHFR gene was PCR-amplified using primers that annealed to
regions just outside the 50 and 30 end of the ecDHFR gene. PCR products
were then subcloned into the pBMN YFP plasmids and transformed into
E. coli Top10 cells. For the N-terminal ecDHFR DD library, 48 randomly chosen
clones were further characterized in mammalian cells. The plasmid DNA was
isolated from bacteria and stably transduced into NIH 3T3 cells using the
retroviral expression system described below. The cells were dosed with
solvent or 10 mM TMP (1:1000 dilution of 10 mM stock in DMSO), and only
the cells that displayed low YFP fluorescence in the absence of TMP and
high levels of YFP expression in the presence of TMP were sequenced.
Thirty-six clones were similarly isolated and validated from the C-terminal
DD library. Sequence information is provided in Tables S1 and S2.
Cell Culture, Transfections, and Transductions
The NIH 3T3 cell line was cultured in DMEM supplemented with 10%
donor bovine serum (Invitrogen), 2 mM glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin. All stable cell lines were created using the
Phoenix ecotropic packaging cell line that was transfected using a standard
lipofectamine 2000 protocol. Viral supernatants were harvested 48 hr post-
transfection, filtered, and supplemented with 4 mg/ml polybrene. NIH 3T3 cells
were incubated with viral supernatant for 4 hr at 37C. Cells were cultured in
growth media for 48 hr to allow for viral integration and then assayed assevier Ltd All rights reserved
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A Novel DHFR-Derived Destabilizing Domaindescribed. For fluorescence decay kinetics experiments, TMP was removed
from the cells by first harvesting the cells with trypsin and then washing TMP
from the cells by repeated centrifugation, aspiration, and resuspension in
TMP-free media. Alternatively, washing adherent cells once with TMP-free
media followed by incubating cells in media ‘‘conditioned’’ with bacterially
expressed wild-type ecDHFR protein at 5 mM concentration is even more
effective for switching to nonpermissive conditions.
Flow Cytometry
Twenty-four hours prior to analysis, transduced NIH 3T3 cells were plated and
treated with TMP as described. For cell lines expressing fluorescent proteins,
cells were removed from the plate using trypsin and resuspended in growth
media to avoid aggregation of the cells. Transmembrane protein expressing
cell lines were removed from the plate using 2 mM EDTA in 1 3 PBS, then
treated with fluorescently labeled antibody prior to analysis. Cells were
analyzed at the Stanford Shared FACS Facility with 10,000 events
represented.
Imaging
Tunability experiment was conducted on Zeiss Axioskop 2 epifluorescence
microscope equipped with a QICAM FAST 1394 digital CCD camera.
Rat Models
Lentiviral vectors were constructed using Gateway technology (Invitrogen).
The human CMV promoter was placed upstream of the appropriate fusion
gene in the lentiviral backbone 2k7neo (Suter et al., 2006). The vectors were
produced and then titered using quantitative PCR as described previously
(Nielsen et al., 2009). Adult female Sprague-Dawley rats were injected with
lentivirus (6 3 104 TU in 2 ml vehicle) was injected into each striatum of adult
(225 g) rats (n = 6). rLV encoding the R12Y/Y100I-YFP fusion was injected
into the left striatum and rLV encoding YFP-N18T/A19V was injected into
the right striatum. The injections were performed in two 1 ml deposits
along a single injection tract at the coordinates: anteroposterior = +0.5 mm;
mediolateral = ±3.0 mm relative to bregma and dorsoventral = 5.0 and
4.0 mm, calculated from the dural surface. The injection flow rate was
0.4 mL/min and the glass capillary was kept in place for 1min between deposits
and 3 min after the second deposit before retraction. Rats were housed at two
or three per cage under a 12 hr light:dark cycle with ad libitum access to food
and water. Half of the animals received TMP in the drinking water (TMP emul-
sion 10 mg/ml, with a final concentration of 0.2 mg/ml in water) for 3 weeks,
upon which animals were sacrificed by sodium pentobarbital euthanasia and
transcardially perfused with paraformaldehyde.
Immunohistochemistry
The fixed brain tissue was cut by freezing microtome into 40 mm coronal slices
for free floating immunohistochemical staining for YFP expression. The
sections were quenched in 3% H2O2 and 10% methanol, preincubated in
5% goat serum, and incubated overnight at room temperature with polyclonal
GFP antibody that cross-reacts with YFP.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and one table and can be found
with this article online at doi:10.1016/j.chembiol.2010.07.009.
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